Statement: In total more than 5 patients in the primary trial and the secondary trial experienced Earache.
Primary_evidence: Adverse Events 1:   Total: 107/383 (27.94%)   Anaemia 4/383 (1.04%)   Febrile neutropenia 7/383 (1.83%)   Haemoytique anaemia 0/383 (0.00%)   Leukopenia 1/383 (0.26%)   Neutropenia 6/383 (1.57%)   Thrombocytopenia 2/383 (0.52%)   Anginal pectoris 1/383 (0.26%)   Cardiomyopathy 0/383 (0.00%)   Ear pain 0/383 (0.00%)   Abdominal distension 1/383 (0.26%)   Abdominal pain 6/383 (1.57%) Adverse Events 2:   Total: 85/383 (22.19%)   Anaemia 3/383 (0.78%)   Febrile neutropenia 2/383 (0.52%)   Haemoytique anaemia 0/383 (0.00%)   Leukopenia 0/383 (0.00%)   Neutropenia 1/383 (0.26%)   Thrombocytopenia 1/383 (0.26%)   Anginal pectoris 0/383 (0.00%)   Cardiomyopathy 1/383 (0.26%)   Ear pain 1/383 (0.26%)   Abdominal distension 0/383 (0.00%)   Abdominal pain 3/383 (0.78%)
Secondary_evidence: Adverse Events 1:   Total: 427/2002 (21.33%)   ANAEMIA 13/2002 (0.65%)   BONE MARROW FAILURE 1/2002 (0.05%)   DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%)   FEBRILE NEUTROPENIA 1/2002 (0.05%)   THROMBOCYTOPENIA 11/2002 (0.55%)   ACUTE CORONARY SYNDROME 3/2002 (0.15%)   ANGINA PECTORIS 1/2002 (0.05%)   CARDIAC ARREST 1/2002 (0.05%)   CARDIAC FAILURE 1/2002 (0.05%)   CARDIAC TAMPONADE 1/2002 (0.05%) Adverse Events 2:   Total: 36/181 (19.89%)   ANAEMIA 0/181 (0.00%)   BONE MARROW FAILURE 0/181 (0.00%)   DISSEMINATED INTRAVASCULAR COAGULATION 0/181 (0.00%)   FEBRILE NEUTROPENIA 0/181 (0.00%)   THROMBOCYTOPENIA 10/181 (5.52%)   ACUTE CORONARY SYNDROME 1/181 (0.55%)   ANGINA PECTORIS 0/181 (0.00%)   CARDIAC ARREST 0/181 (0.00%)   CARDIAC FAILURE 0/181 (0.00%)   CARDIAC TAMPONADE 0/181 (0.00%)